Restricted accessResearch articleFirst published online 1997-8
A randomized study comparing mitomycin C,mitomycin C plus epirubicin and mitomycin C plus interferon-alpha-2 in the intravesical prophylaxis of superficial bladder tumour recurrences
– After TUR of superficial bladder tumours (G1-G3, Ta-T1), 121 patients were randomized in three groups of intravesical treatment: mitomycin C alone, mitomycin C plus epirubicin, mitomycin C plus interferon-alpha-2. At a mean follow-up of 53 months, 64 patients (52.8%) showed a recurrence. A trend (p < 0.02) in favour of the combination of mitomycin C and epirubicin was evident. The higher efficacy of this association was particularly evident when patients with primary tumours were excluded from the statistical analysis.
FukuiI., SelcineH., KiharaK., YamadaT., TakeuchiS., YokokawaM., KawaiT., HosodaK., OhwadaF., SuzukiS., OshimaH.: Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder. J. Urol., 141: 531–533, 1989.
2.
CerniliN., PunzoG., GattoA.: Profilassi delle neoplasie superficiali mediante l'impiego endovescicale di tre farmaci in successione. Risultati preliminari. Acta Urol. Ital., 4 (suppl. 1): 147–150, 1989.
3.
BoccardoF., CannataD., RubagottiA., GuarneriD., DecensiA., CanobbioL., CurottoA., MartoranaG., PegoraroC., SelvaggiF., SalviaG., ComeriG., BonoA., BorellaT., GiulianiL.: Prophylaxis of superficial bladder cancer with mitomycin or interferon-alfa-2b: results of a multicentric Italian study. J. Clin. Oncol., 12: 7–13, 1994.
4.
SerrettaV., CorselliG., PiazzaB., LioD., SalernoS., Pavone-MacalusoM.: Correlation between clinical response and urinary interleukins (IL-1, IL-2, IL-4) levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study. Urol. Res, 21: 353–357, 1993.
